Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Diabetes
•
Endocrinology
•
Obesity Medicine
•
General Endocrinology
•
Primary Care
Should we be using body fat percentage instead of BMI for determining patients' risk of metabolic syndrome?
https://pubmed.ncbi.nlm.nih.gov/38747476/
Related Questions
Do you recommend the use of GLP1 R agonist therapy in patients with T1DM for weight loss?
Do you recommend routinely monitoring pancreatic markers such as amylase and lipase while receiving GLP1 R agonist or dual agonist therapies to determine their risk of pancreatitis?
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
What is the typical timeline for remission of autoimmune hypoglycemia?
How do you counsel patients on the use of compounded weight loss medications?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
Can rapid weight loss following GLP1 R agonist therapy lead to postprandial hypoglycemia and if so, what are the treatment options outside of dietary modifications?
Should we recommend SGLT2i initiation at discharge to all patients hospitalized with acute myocardial infarction?
What is the optimal BP target for patients with diabetes and hypertension to reduce their risk of MI/stroke?
Do you recommend the use of Korlym (Mifepristone) for patients with difficult to control diabetes and evidence of mild endogenous hypercortisolism of unknown source?
